SMMT Logo

Summit Therapeutics Inc. (SMMT) 

NASDAQ
Market Cap
$15.18B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
118 of 776
Rank in Industry
80 of 433

Largest Insider Buys in Sector

SMMT Stock Price History Chart

SMMT Stock Performance

About Summit Therapeutics Inc.

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae …

Insider Activity of Summit Therapeutics Inc.

Over the last 12 months, insiders at Summit Therapeutics Inc. have bought $840,698 and sold $0 worth of Summit Therapeutics Inc. stock.

On average, over the past 5 years, insiders at Summit Therapeutics Inc. have bought $125.54M and sold $321,463 worth of stock each year.

Highest buying activity among insiders over the last 12 months: Dhingra Ankur (Chief Financial Officer) — $838,508. Zanganeh Mahkam (Chief Executive Officer) — $421,444.

The last purchase of 80,321 shares for transaction amount of $298,594 was made by Zanganeh Mahkam (Chief Executive Officer) on 2024‑03‑27.

List of Insider Buy and Sell Transactions, Summit Therapeutics Inc.

2024-03-27PurchaseChief Executive Officer
80,321
0.0113%
$3.72$298,594+140.11%
2024-03-26PurchaseChief Financial Officer
100,000
0.0143%
$3.75$375,000+136.36%
2024-03-26PurchaseChief Executive Officer
30,000
0.0043%
$3.75$112,500+136.36%
2023-12-13PurchaseChief Financial Officer
20,400
0.0027%
$2.17$44,254+96.60%
2023-12-12PurchaseChief Executive Officer
5,000
0.0007%
$2.07$10,350+109.47%
2023-10-13PurchaseChief Operating Officer
2.98M
0.4265%
$1.68$5M+147.62%
2023-03-08PurchaseCo-CEO & President
23.53M
4.2977%
$1.05$24.7M+26.64%
2023-03-07PurchaseChief Financial Officer
196,362
0.0395%
$1.05$206,180+39.49%
2023-03-06PurchaseChief Executive Officer
376.49M
75.2052%
$1.05$395.31M+38.49%
2022-08-16PurchaseChief Executive Officer
94.85M
61.3078%
$0.97$92M+70.30%
2022-08-16PurchaseCo-CEO & President
1.03M
0.6664%
$0.97$999,997+70.30%
2022-08-16PurchaseChief Financial Officer
37,685
0.0244%
$0.97$36,554+70.30%
2021-05-12PurchaseChief Executive Officer
11.37M
12.0109%
$5.24$59.56M-6.40%
2021-05-12PurchaseChief Operating Officer
389,077
0.4112%
$5.24$2.04M-6.40%
2020-11-30SaleChief Scientific Officer
13,713
0.0195%
$4.44$60,886+36.67%
2020-11-27SaleChief Scientific Officer
29,569
0.043%
$4.39$129,808+41.94%
2020-11-25SaleChief Scientific Officer
12,070
0.0175%
$4.32$52,142+43.93%
2020-11-24SaleChief Scientific Officer
11,374
0.0164%
$4.21$47,885+46.08%
2020-11-23SaleChief Scientific Officer
6,987
0.01%
$4.40$30,743+39.77%
2020-11-06PurchaseChief Executive Officer
14.07M
20.8007%
$3.34$47M+89.54%

Insider Historical Profitability

43.58%
Zanganeh MahkamChief Executive Officer
24923800
3.3814%
$20.6060+30.18%
Dhingra AnkurChief Financial Officer
354958
0.0482%
$20.6040+54.89%
DUGGAN ROBERT WChief Executive Officer
552354161
74.9366%
$20.6040+47.98%
Soni Manmeet SinghChief Operating Officer
2976190
0.4038%
$20.6010

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
BlackRock$40.67M1.49.82M+0.66%+$264,786.11<0.01
State Street$33.59M1.168.11M+230.36%+$23.42M<0.01
Fidelity Investments$33.01M1.147.97M+85,445.28%+$32.98M<0.01
The Vanguard Group$30.09M1.047.27M+3.63%+$1.05M<0.01
Geode Capital Management$13.05M0.453.15M+2.16%+$276,271.19<0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.